Drug updated on 12/11/2024
| Dosage Form | Tablet (oral; 100 mg, 150 mg, 200 mg) |
| Drug Class | Kinase inhibitors |
| Ongoing and Completed Studies | ClinicalTrials.gov |
Indication
- Indicated for the treatment of intermediate or high-risk myelofibrosis (MF), including primary MF or secondary MF [postpolycythemia vera (PV) and post-essential thrombocythemia (ET)], in adults with anemia
Latest News
Summary
- This summary is based on the review of one systematic review/meta-analysis. [1]
- Spleen Volume Reduction: Momelotinib demonstrated efficacy comparable to ruxolitinib and fedratinib in reducing spleen volume in first-line treatment for myelofibrosis. Pacritinib was less effective in first-line therapy but showed effectiveness in second-line therapy following ruxolitinib exposure.
- Effect on Anemia and Thrombopenia: Momelotinib exhibited positive effects on anemia and was associated with lower toxicity on platelets compared to fedratinib and ruxolitinib, suggesting a potentially safer profile for managing hematological side effects.
- Momelotinib demonstrated a favorable safety profile, showing less toxicity on erythrocytes (ANEMIA) and platelets (THROMBOPENIA) compared to other Janus Kinase (JAK) inhibitors such as ruxolitinib and fedratinib, suggesting reduced hematological side effects.
- Specific safety concerns or adverse effects beyond anemia and thrombopenia were not detailed in the provided abstract.
- There is no population types or subgroups information available in the reviewed documents.
Product Monograph / Prescribing Information
| Document Title | Year | Source |
|---|---|---|
| Ojjaara (momelotinib) Prescribing Information. | 2023 | GlaxoSmithKline Durham, NC |
Systematic Reviews / Meta-Analyses
| Document Title | Year | Source |
|---|---|---|
| Efficacy and tolerability of Janus kinase inhibitors in myelofibrosis: a systematic review and network meta-analysis | 2021 | Blood Cancer Journal |